CA2702635A1 - A new biomarker for monitoring development of diseases and assessing the efficacy of therapies - Google Patents

A new biomarker for monitoring development of diseases and assessing the efficacy of therapies Download PDF

Info

Publication number
CA2702635A1
CA2702635A1 CA2702635A CA2702635A CA2702635A1 CA 2702635 A1 CA2702635 A1 CA 2702635A1 CA 2702635 A CA2702635 A CA 2702635A CA 2702635 A CA2702635 A CA 2702635A CA 2702635 A1 CA2702635 A1 CA 2702635A1
Authority
CA
Canada
Prior art keywords
disease
sample
protein
patient
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2702635A
Other languages
English (en)
French (fr)
Inventor
Sirpa Jalkanen
Marko Salmi
Markku Jalkanen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Faron Pharmaceuticals Oy
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2702635A1 publication Critical patent/CA2702635A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
CA2702635A 2007-10-24 2008-10-15 A new biomarker for monitoring development of diseases and assessing the efficacy of therapies Abandoned CA2702635A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20070795 2007-10-24
FI20070795A FI20070795A0 (fi) 2007-10-24 2007-10-24 Uusi biomarkkeri sairauksien kehittämisen tarkkailuun ja terapioiden tehon arviointiin
PCT/FI2008/050576 WO2009053523A1 (en) 2007-10-24 2008-10-15 A new biomarker for monitoring development of diseases and assessing the efficacy of therapies

Publications (1)

Publication Number Publication Date
CA2702635A1 true CA2702635A1 (en) 2009-04-30

Family

ID=38656804

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2702635A Abandoned CA2702635A1 (en) 2007-10-24 2008-10-15 A new biomarker for monitoring development of diseases and assessing the efficacy of therapies

Country Status (14)

Country Link
US (1) US20100209942A1 (https=)
EP (2) EP2201376B1 (https=)
JP (2) JP4982610B2 (https=)
KR (2) KR20100059902A (https=)
CA (1) CA2702635A1 (https=)
CY (2) CY1113403T1 (https=)
DK (2) DK2201376T3 (https=)
ES (2) ES2532361T3 (https=)
FI (1) FI20070795A0 (https=)
HR (2) HRP20120743T1 (https=)
PL (2) PL2201376T3 (https=)
PT (2) PT2201376E (https=)
SI (2) SI2201376T1 (https=)
WO (1) WO2009053523A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2240781T3 (en) 2008-01-18 2018-03-26 Harvard College METHODS FOR DETECTING DISEASE OR STATE SIGNATURES IN BODY FLUIDS
AU2011280997A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
CA2806304A1 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting prenatal or pregnancy-related diseases or conditions
EP2596349B1 (en) 2010-07-23 2017-12-13 President and Fellows of Harvard College Methods of detecting cardiovascular diseases or conditions
EP2596134B1 (en) 2010-07-23 2020-04-08 President and Fellows of Harvard College Methods of detecting diseases or conditions using phagocytic cells
WO2012012693A2 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods for detecting signatures of disease or conditions in bodily fluids
WO2013188846A1 (en) 2012-06-15 2013-12-19 Harry Stylli Methods of detecting diseases or conditions
EP2861788B1 (en) 2012-06-15 2018-10-10 Progenity, Inc. Methods of detecting diseases or conditions using circulating diseased cells
DK2956772T3 (en) * 2013-02-14 2018-08-13 Faron Pharmaceuticals Oy A PROCEDURE FOR DETERMINING ACUTE LUNG FAILURE (ARDS) RELATED BIOMARKERS, A PROCEDURE FOR MONITORING DEVELOPMENT AND TREATMENT OF ARDS BY A PATIENT
US11585814B2 (en) 2013-03-09 2023-02-21 Immunis.Ai, Inc. Methods of detecting prostate cancer
EP2965077B1 (en) 2013-03-09 2022-07-13 Harry Stylli Methods of detecting cancer
MA40636A (fr) 2014-09-11 2015-09-11 Colleen Kelly Procédés pour détecter le cancer de la prostate
JP6668345B2 (ja) 2014-11-21 2020-03-18 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 修飾された重鎖定常領域を含む抗体
MY189836A (en) 2014-11-21 2022-03-11 Bristol Myers Squibb Co Antibodies against cd73 and uses thereof
GB201706747D0 (en) 2017-04-27 2017-06-14 Queen Mary Method and apparatus for determining the efficacy of statins for treating inflammatory diseases in idividual patients

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2228970A1 (en) * 1995-08-18 1997-02-27 Donald W. Landry Detection of organic compounds through regulation of antibody-catalyzed reactions
AU7310496A (en) * 1995-10-13 1997-04-30 Imperial College Of Science, Technology And Medicine Methods for predicting the outcome of persistent hbv infection and the outcome of cytokine therapy
HUP0002003A3 (en) * 2000-05-24 2003-01-28 Pronuk Biotechnologia Kft Process and reagent-kit for determining of 5'-nucleotidase activity
US20030099608A1 (en) * 2001-03-27 2003-05-29 Presnell Scott R. Human cytokine receptor
WO2004079013A1 (en) * 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
FI20030467A0 (fi) * 2003-03-28 2003-03-28 Sirpa Jalkanen Menetelmä tulehdustilojen hoitamiseen
WO2004084933A1 (en) * 2003-03-28 2004-10-07 Faron Pharmaceuticals Oy Elevation of adenosine level by cytokine-induced expression of cd73
CN1835962A (zh) * 2003-06-03 2006-09-20 加利福尼亚大学董事会 利用乙酰化二糖治疗疾病的组合物与方法
ATE520979T1 (de) * 2005-08-24 2011-09-15 Bristol Myers Squibb Co Biomarker und verfahren zur bestimmung der empfindlichkeit gegenüber modulatoren des egf(epidermal growth factor)-rezeptors
FI20051003A0 (fi) 2005-10-07 2005-10-07 Faron Pharmaceuticals Oy Menetelmä iskemiareperfuusiovaurion tai monielinhäiriön hoitamiseksi tai estämiseksi
WO2007107598A1 (en) * 2006-03-21 2007-09-27 Heinrich-Heine-Universität Düsseldorf Phosphorylated a2a receptor agonists
EP3796002B1 (en) * 2006-07-14 2023-11-22 The Regents of The University of California Cancer biomarkers and methods of use thereof

Also Published As

Publication number Publication date
EP2503338A3 (en) 2013-03-13
SI2201376T1 (sl) 2012-09-28
HRP20120743T1 (hr) 2012-10-31
EP2201376A1 (en) 2010-06-30
PL2503338T3 (pl) 2015-06-30
JP2011501176A (ja) 2011-01-06
EP2503338B1 (en) 2014-12-24
PT2503338E (pt) 2015-03-05
JP2012159514A (ja) 2012-08-23
SI2503338T1 (sl) 2015-06-30
CY1116089T1 (el) 2017-02-08
FI20070795A0 (fi) 2007-10-24
JP4982610B2 (ja) 2012-07-25
HRP20150181T1 (hr) 2015-06-19
DK2503338T3 (en) 2015-03-09
CY1113403T1 (el) 2016-06-22
US20100209942A1 (en) 2010-08-19
KR20100059902A (ko) 2010-06-04
KR20160029869A (ko) 2016-03-15
ES2389751T3 (es) 2012-10-31
EP2503338A2 (en) 2012-09-26
PL2201376T3 (pl) 2013-01-31
WO2009053523A1 (en) 2009-04-30
EP2201376A4 (en) 2011-03-23
EP2201376B1 (en) 2012-08-08
ES2532361T3 (es) 2015-03-26
JP5619810B2 (ja) 2014-11-05
PT2201376E (pt) 2012-08-20
DK2201376T3 (da) 2012-10-15

Similar Documents

Publication Publication Date Title
EP2201376B1 (en) A new biomarker for monitoring development of diseases and assessing the efficacy of therapies
Diamant et al. Toward clinically applicable biomarkers for asthma: an EAACI position paper
Romagnani et al. CXCL10: a candidate biomarker in transplantation
US8975081B2 (en) Biomarker for monitoring development of diseases and assessing the efficacy of therapies
Chaiworapongsa et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia: Young Investigator Award
CA2744434C (en) Methods, devices and kits for detecting or monitoring acute kidney injury
Alturaiki et al. Assessment of IL‐1β, IL‐6, TNF‐α, IL‐8, and CCL 5 levels in newly diagnosed Saudi patients with rheumatoid arthritis
JP2025019061A (ja) 術後有害事象の診断または予後
JP2010519898A (ja) ライノウイルス感染を制御するための化合物の同定方法及び標的
US20090011444A1 (en) Detection and diagnosis of inflammatory disorders
Tian et al. Serum levels of procalcitonin as a biomarker for differentiating between sepsis and systemic inflammatory response syndrome in the neurological intensive care unit
Koczulla et al. Alpha-1 antitrypsin is elevated in exhaled breath condensate and serum in exacerbated COPD patients
Engebretsen et al. Acute hypobaric hypoxia (5486 m) induces greater pulmonary HIF-1 activation in hilltop compared to madison rats
Gatselis et al. Calprotectin serum levels on admission and during follow-up predict severity and outcome of patients with COVID-19: A prospective study
CN110678757B (zh) 诊断或监测肾功能或诊断肾功能障碍的方法
US20110033876A1 (en) Method for diagnosing pulmonary artery hypertension
WO2011125858A1 (ja) バイオマーカー
Szalardy et al. Unlike PPARgamma, neither other PPARs nor PGC-1alpha is elevated in the cerebrospinal fluid of patients with multiple sclerosis
CN117529664A (zh) 用于预测脓毒症和脓毒性休克的方法
Jedynak et al. Serum concentrations of MCP-1 and RANTES in patients during aortic surgery: the relationship with ischemia-reperfusion
Sumi et al. Regional variations in allergen-induced airway inflammation corresponds to changes in soluble guanylyl cyclase heme and expression of heme-oxygenase-1
Dutta et al. Diagnosis of infected pancreatic necrosis: A review of the role of blood biomarkers
Sandström et al. Endotoxin receptor CD14 in PiZ α-1-antitrypsin deficiency individuals
TWI728427B (zh) 評估表皮生長因子受體抑制劑引發皮膚藥物不良反應風險的方法、其檢測套組及其用途
Xu et al. Longitudinal relationships between serum ferritin and prognosis among severe community-acquired

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130827

FZDE Discontinued

Effective date: 20201005